| U19 is growth inhibitory and tumor suppressive and that the disruption of androgen-dependent growth inhibition via U19 down-regulation is commonly associated with prostate cancer progression. | prostate, |
| cooperation of VHL and EAF2 may be critical for angiogenic regulation of the liver and prostate, and concurrent loss of these two tumor suppressors may result in a pro-angiogenic phenotype. | liver,prostate, |
| Regulation of tumor suppressor EAF2 polyubiquitination by ELL1 and SIAH2 in prostate cancer cells | prostate, |
| Findings provide further evidence that ELL2 is a potential tumor suppressor frequently down-regulated in clinical prostate cancer specimens and provides new insights into regulation of ELL2 protein level by polyubiquitination and EAF2 binding. | prostate, |
| Candidate Tumor Suppressor Gene EAF2 is Mutated in Colorectal and Gastric Cancers | gastric,colorectal, |
| Correction: Regulation of tumor suppressor EAF2 polyubiquitination by ELL1 and SIAH2 in prostate cancer cells | prostate, |
| Inhibition of 5alpha-reductase during prostatic tumor regrowth enhances the expression of U19/Eaf2, an androgen-regulated tumor suppressor. | None |
| A novel role for Eaf1 and Eaf2 in inhibiting canonical Wnt/beta-catenin signaling, which might form the mechanistic basis for Eaf1 and Eaf2 tumor suppressor activity. | None |
| study unveiled a previously unrecognized link of Eaf1/2 genes with TGF-beta and P53 in vertebrates and demonstrated a conservation of TGF-beta suppression activity for Eaf1/2 family genes from fish to mammals, which might shed some light on the molecular mechanistic basis of Eaf1 and Eaf2 in tumor suppression. | None |